Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

PURPOSE: We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an oral selective inhibitor of nuclear export compound, in patients with advanced soft tissue or bone sarcoma with progressive disease. PATIENTS AND METHODS: Fifty-four patients were treated with o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Gounder, Mrinal M., Zer, Alona, Tap, William D., Salah, Samer, Dickson, Mark A., Gupta, Abha A., Keohan, Mary Louise, Loong, Herbert H., D’Angelo, Sandra P., Baker, Stephanie, Condy, Mercedes, Nyquist-Schultz, Kjirsten, Tanner, Lanier, Erinjeri, Joseph P., Jasmine, Francis H., Friedlander, Sharon, Carlson, Robert, Unger, Thaddeus J., Saint-Martin, Jean-Richard, Rashal, Tami, Ellis, Joel, Kauffman, Michael, Shacham, Sharon, Schwartz, Gary K., Abdul Razak, Albiruni Ryan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321073/
https://ncbi.nlm.nih.gov/pubmed/27458288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.6346
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados